Last reviewed · How we verify

Ukrainian Medical Stomatological Academy — Portfolio Competitive Intelligence Brief

Ukrainian Medical Stomatological Academy pipeline: 1 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Ramipril 5 MG Ramipril 5 MG marketed
Oral L-arginine aspartate administration Oral L-arginine aspartate administration phase 3 Amino acid supplement / Nitric oxide donor Nitric oxide synthase (NOS) Cardiovascular
Oral L-ornithine aspartate administration Oral L-ornithine aspartate administration phase 3 Amino acid supplement Gastroenterology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Air Force Military Medical University, China · 1 shared drug class
  2. Elijah W. Stommel · 1 shared drug class
  3. Hadassah Medical Organization · 1 shared drug class
  4. Keith D Lindor, M.D. · 1 shared drug class
  5. McMaster University · 1 shared drug class
  6. Radboud University Medical Center · 1 shared drug class
  7. The University of Texas at Arlington · 1 shared drug class
  8. University Hospital, Strasbourg, France · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Ukrainian Medical Stomatological Academy:

Cite this brief

Drug Landscape (2026). Ukrainian Medical Stomatological Academy — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ukrainian-medical-stomatological-academy. Accessed 2026-05-17.

Related